Log in to your Inderes Free account to see all free content on this page.
Prostatype Genomics
10.7
SEK
-3.6 %
PROGEN
First North Stockholm
Medical Equipment & Services
Health Care
3 following
-3.6%
-3.6%
+42.67%
-17.69%
-14.04%
-76.02%
-98.76%
-
-98.41%
Prostatype Genomics is active in medical technology. The company specializes in the development of medical-technical genetic tests that are used for identification, analysis, and further follow-up of prostate cancer. In addition to the main business, service and associated ancillary services are also offered. The operations are found worldwide with the largest presence in the Nordic market.
Read moreMarket cap
73.14M SEK
Turnover
181.87K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
13.2.
2025
Annual report '24
ShowingAll content types
New shares from the exercise of Prostatype Genomics AB’s warrants of series TO 4 is now registered at the Swedish Companies Registration Office
Health economics study with Prostatype® peer-reviewed and approved for publishing in renown scientific journal
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio